Electric Countershock: Clinical Trials

3 trials of Electric Countershock, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

3 completed. 3 Phase 3, 1 Phase 2.

By phase and status

PhaseTrialsStatus
Phase 33Completed 3
Phase 21Completed 1

Follow Electric Countershock: new trials by email Literature Review of Electric Countershock trials Research Report on Electric Countershock

Trials (filtered) newest first · largest first

All 3 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Rate Control Versus Rhythm Control For Postoperative Atrial Fibrillation
Amiodarone, DC-cardioversion, Rate Control - Postoperative Atrial Fibrillation
Phase 3CompletedIcahn School of Medicine at Mount Sinai5232014-05-012019-03-15
Risk of Stroke and Silent Cerebrovascular Thromboembolism After Cardioversion of Atrial Fibrillation
Cardioversion, Oral Anticoagulant - Atrial Fibrillation, Cardioversion
Phase 3CompletedSuleyman Demirel University1122013-08-012024-11-15
Safety and Effectiveness of Cardiac Resynchronization Therapy With Defibrillation
Cardiac Resynchronization Therapy with Defibrillation - Heart Failure, Congestive, Ventricular Fibrillation
Phase 2 / Phase 3CompletedBoston Scientific Corporation5811998-02-012007-01-25

Conditions studied

Atrial Fibrillation (2)  ·  Arrhythmias, Cardiac (1)  ·  Atrial Flutter (1)  ·  Heart Failure (1)  ·  Stroke (1)  ·  Tachycardia, Ventricular (1)  ·  Ventricular Fibrillation (1)

Sponsors

Boston Scientific Corporation (1)  ·  Icahn School of Medicine at Mount Sinai (1)  ·  Suleyman Demirel University (1)

Countries

United States (2)  ·  Canada (1)  ·  Turkey (Türkiye) (1)

Top investigators

John Boehmer, MD (1)  ·  Leslie A Saxon, MD (1)  ·  Mehmet Ozaydin, Professor,MD (1)  ·  Patrick T O'Gara, MD (1)  ·  Richard Wiesel, MD (1)  ·  Steven Higgins, MD (1)  ·  Teresa De Marco, MD (1)

Results publications

PMID 14563591, PMID 27043047, PMID 29043263

NIH funding

U01HL088942 (1)